PMID- 3857019
OWN - NLM
STAT- MEDLINE
DCOM- 19850517
LR  - 20210526
IS  - 0066-4804 (Print)
IS  - 1098-6596 (Electronic)
IS  - 0066-4804 (Linking)
VI  - 27
IP  - 2
DP  - 1985 Feb
TI  - Enhancement by clofazimine and inhibition by dapsone of production of 
      prostaglandin E2 by human polymorphonuclear leukocytes in vitro.
PG  - 257-62
AB  - The effects of the antileprosy agents clofazimine and dapsone (1 to 10 
      micrograms/ml) on the spontaneous and stimulated release of prostaglandin E2 (PG 
      E2) by human polymorphonuclear leukocytes (PMNL) in vitro have been investigated. 
      PMNL were obtained from normal adult volunteers and three patients with leprosy 
      (two borderline lepromatous and one subpolar lepromatous leprosy). The synthetic 
      chemotactic tripeptide N-formyl-L-methionyl-L-leucyl-L-phenylalanine (FMLP) at a 
      concentration of 10(-7) M was used as the stimulant of PG E2 synthesis. None of 
      the test agents at the concentrations used inhibited the binding of radiolabeled 
      FMLP to PMNL. However, dapsone at 5 and 10 micrograms/ml inhibited the 
      spontaneous and FMLP-induced release of PG E2 by PMNL. Clofazimine, on the other 
      hand, significantly increased both the spontaneous and the FMLP-induced synthesis 
      of PG E2 by PMNL. The enhancing effects of clofazimine on FMLP-mediated synthesis 
      of PG E2 were particularly striking and were observed at concentrations of 1 to 
      10 micrograms of the drug per ml. Measurements of PMNL spontaneous and 
      FMLP-induced synthesis of PG E2 in the presence of both clofazimine and dapsone 
      (5 micrograms/ml) indicated that the two drugs are mutually antagonistic. PMNL 
      from both normal control subjects and patients with leprosy were equally 
      sensitive to these effects of clofazimine and dapsone. The immunostimulatory and 
      immunosuppressive properties of dapsone and clofazimine, respectively, may be 
      related to the opposite effects of these agents on PG E2 synthesis in human 
      leukocytes.
FAU - Anderson, R
AU  - Anderson R
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Antimicrob Agents Chemother
JT  - Antimicrobial agents and chemotherapy
JID - 0315061
RN  - 0 (Prostaglandins E)
RN  - 59880-97-6 (N-Formylmethionine Leucyl-Phenylalanine)
RN  - 8W5C518302 (Dapsone)
RN  - D959AE5USF (Clofazimine)
RN  - K7Q1JQR04M (Dinoprostone)
RN  - VJT6J7R4TR (Rifampin)
SB  - IM
MH  - Clofazimine/*pharmacology
MH  - Dapsone/*pharmacology
MH  - Dinoprostone
MH  - Female
MH  - Humans
MH  - In Vitro Techniques
MH  - Kinetics
MH  - Male
MH  - N-Formylmethionine Leucyl-Phenylalanine/pharmacology
MH  - Neutrophils/drug effects/*metabolism
MH  - Prostaglandins E/*biosynthesis
MH  - Rifampin/pharmacology
PMC - PMC176249
EDAT- 1985/02/01 00:00
MHDA- 1985/02/01 00:01
PMCR- 1985/02/01
CRDT- 1985/02/01 00:00
PHST- 1985/02/01 00:00 [pubmed]
PHST- 1985/02/01 00:01 [medline]
PHST- 1985/02/01 00:00 [entrez]
PHST- 1985/02/01 00:00 [pmc-release]
AID - 10.1128/AAC.27.2.257 [doi]
PST - ppublish
SO  - Antimicrob Agents Chemother. 1985 Feb;27(2):257-62. doi: 10.1128/AAC.27.2.257.